Skip to main content
Equibles
DHR logo

DHR · Danaher Corp /De/

Track DHR — free

Use DHR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research DHR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$211.81 -0.69 (-0.32%) At close · Sep 18
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$147.37B
Shares
702.99M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$211.81 Open$212.64 Day$210.10–214.98 52W close$161.91–242.05 Avg vol 30d3.5M Short int9.6M · 1.4% float · 2.8d Short vol37% Last earningsJul 21, 2026 DataJan 2020–Sep 2026 Filing10-Q · Jul 21

Up next

Next earnings call
Oct 20, 2026 Est · unconfirmed · in 4 wks
Latest filing: 10-Q
filed Jul 21, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$25.11B
Trailing 12 months
Net income (TTM)
$4.00B
Trailing 12 months
Revenue growth YoY
+5.5%
Year over year
Operating margin
20.4%
Trailing 12 months
P / E (TTM)
37.6
Trailing earnings · reciprocal yield 2.7%
FCF yield
3.7%
TTM · current market cap
Return on invested capital
5.7%
Trailing 12 months
Net cash
−$22.21B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-1.6%
Year over year · fewer shares
Price change (1Y)
+8.5%
Trailing year
Short interest
1.4%
Latest settlement · 2.8 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Weak Sentiment Bearish Fundamentals Fair Quant / Vol Moderate
Market backdrop VIX 14.8 · calm Equity put/call 0.58
Technical
price trend
Buy
50 / 200-day cross Golden cross
Price vs 200-day avg +5%
above
Price vs 50-day avg +4%
above
RSI (14) 57
neutral
MACD trend Negative
52-week position 62%
mid-range
Momentum
relative strength
Weak
1-month return −2%
trailing
6-month return +17%
trailing
YTD return −7%
this year
Relative strength −3%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) Golden cross
50d $204 › 200d $202 — 50d above 200d
Institutional flow Distributing
-3% holders QoQ · +154 funds added
Insider flow Distributing
Net -$12.7M over 90 days · 100% sells
Short interest Rising
1.37% of float · ▲ +9.8% MoM · 2.8 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr low
2,123 holders — near 3-yr low, contrarian setup
Squeeze score 51
elevated · 0–100
Fundamentals
Fair
Revenue growth +9%
Y/Y
Gross margin 73%
contracting
EPS growth −5%
Y/Y
Free cash flow $5.3B
Valuation P/E 37.2
rich
Balance sheet $13.8B
net debt
Quant / Vol
risk profile
Moderate
Volatility 32%
annualized · 1-yr
Max drawdown −33%
past year
ATR 2.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Jul 21, 2026
third quarter 2026
Non-GAAP core revenue Non-GAAP Initiated 2% – 3%
full year 2026
Non-GAAP core revenue Non-GAAP Initiated 3% – 4%
Three-Month Period Ending September 25, 2026 vs. Comparable 2025
Core sales growth (non-GAAP) - Life Sciences Non-GAAP 3% – 4%
Core sales growth (non-GAAP) - Total Company Non-GAAP 2% – 3%
Core sales growth excluding respiratory testing (non-GAAP) - Tot Non-GAAP 5%
Year Ending December 31, 2026 vs. Comparable 2025 Period
Core sales growth (non-GAAP) - Life Sciences Non-GAAP 3% – 4%
Core sales growth (non-GAAP) - Total Company Non-GAAP 3% – 4%
Prior guidance period ended · from the Earnings Call filed Oct 21, 2021
Total capital expenditures across Danaher · 2021 $1.5B
COVID-related vaccine and therapeutic revenue · 2021 $2B
COVID-related backlog · entering 2022 $2B
Backlog for the bio-process business · 2022 $2B

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 3
50 / 200-day cross
Golden cross Bullish
Price vs 200-day avg
+5% Bullish
Price vs 50-day avg
+4% Bullish
RSI (14)
57 Neutral
MACD trend
Negative Bearish
52-week position
62% Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross) Golden cross
50d $204 › 200d $202 — 50d above 200d
Institutional flow Distributing
-3% holders QoQ · +154 funds added
Insider flow Distributing
Net -$12.7M over 90 days · 100% sells
Short interest Rising
1.37% of float · ▲ +9.8% MoM · 2.8 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr low
2,123 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $162 Now $212 · 62% Range high $242
vs 200-day avg +5% vs 50-day avg +4% 50-day above 200-day golden cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Diagnostics & Research — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
DHR
Danaher Corp /De/
this stock
$147.37B -7.5% +8.5% 37.2 1.4%
TMO
Thermo Fisher Scientific Inc.
 $240.87B +12.4% +14.5% 35.0 1.5%
NTRA
Natera, Inc.
 $53.25B +61.2% -2.8% — 3.8%
IQV
Iqvia Holdings Inc.
 $44.71B +18.2% +41.6% 33.3 2.3%
A
Agilent Technologies, Inc.
 $42.37B +15.0% +6.4% 29.6 2.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
2,123
% held
83.0%
Net QoQ
+6.6M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
1,142
View
Short & Settlement
Short Interest Rising
Shares short
9.6M
Days to cover
2.8d
Change
+858.0K sh
View
Short Volume
Short vol %
37%
As of
Sep 18, 2026
Short Total
View
Fails to Deliver
FTD shares
2
Value
$432
As of
Aug 31, 2026
View
Off-Exchange
Off-exchange %
45.0%
Week of
Aug 10, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$12.7M
Buyers / Sellers
0 / 1
Buyers Sellers
View
Congressional Trades Buy
Member
Alan Armstrong
Amount
$1.0K–$15.0K
Traded
Mar 27, 2026
View
Financials
Financials
Revenue (FY)
$24.6B
Net income (FY)
$3.6B
EPS diluted
$5.05
View
Buybacks
Authorized
shares 35.0M
Remaining
shares 32.0M
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 3, 2026
This year
15
View
Proposed Sales
Value
$658.3K
Shares
3.3K
Filed
Jul 14, 2026
View
Earnings & Events
Earnings Calls
Last call
Jul 21, 2026
View

Performance

5D 20D 120D MTD YTD
DHR +5.8% -1.9% +16.7% -0.8% -7.5%
SPY -0.3% -0.1% +20.1% -0.7% +11.7%
vs SPY +6.2% -1.8% -3.4% -0.1% -19.2%

Capital returns

Declared · upcoming
$0.40 / share · ex Sep 30, 2026
Paid (TTM)
$0.00 / share · 0 payouts
Dividend yield (TTM, derived)
— · no payout in the trailing year
Buyback program · as of Jun 26, 2026
Authorized
shares 35.00M
Spent (derived)
shares 3.00M
Remaining
shares 32.00M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 313616 CUSIP 235851102 13F (30d) 68 filings 36 filers Visit website Investor relations